Interferons‐beta versus glatiramer acetate for relapsing‐remitting multiple sclerosis
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Interferons‐beta Versus Glatiramer Acetate for Relapsing‐remitting Multiple Sclerosis." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/437506/1/Negative_pressure_wound_therapy_for_treating_leg_ulcers:_Cochrane_systematic_review. Accessed 29 March 2024.
Interferons‐beta versus glatiramer acetate for relapsing‐remitting multiple sclerosis. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/437506/1/Negative_pressure_wound_therapy_for_treating_leg_ulcers:_Cochrane_systematic_review. Accessed March 29, 2024.
Interferons‐beta versus glatiramer acetate for relapsing‐remitting multiple sclerosis. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/437506/1/Negative_pressure_wound_therapy_for_treating_leg_ulcers:_Cochrane_systematic_review
Interferons‐beta Versus Glatiramer Acetate for Relapsing‐remitting Multiple Sclerosis [Internet]. In: Cochrane Abstracts. [cited 2024 March 29]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/437506/1/Negative_pressure_wound_therapy_for_treating_leg_ulcers:_Cochrane_systematic_review.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Interferons‐beta versus glatiramer acetate for relapsing‐remitting multiple sclerosis
ID - 437506
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/437506/1/Negative_pressure_wound_therapy_for_treating_leg_ulcers:_Cochrane_systematic_review
DB - Evidence Central
DP - Unbound Medicine
ER -